Used in pharmaceutical research as a key intermediate in the synthesis of tyrosine kinase inhibitors, particularly for targeted cancer therapies. Shows potential in inhibiting epidermal growth factor receptor (EGFR) pathways, making it relevant in the development of treatments for non-small cell lung cancer and other solid tumors. Its structure supports high binding affinity to mutant forms of EGFR, including T790M and C797S, which are associated with resistance to earlier generations of inhibitors. Also employed in structure-activity relationship (SAR) studies to optimize potency, selectivity, and pharmacokinetic properties of novel anticancer agents.